Jacqueline Le Saux
No más puestos en curso
Fortuna: - $ al 30/04/2024
Historial de carrera de Jacqueline Le Saux
Antiguos cargos conocidos de Jacqueline Le Saux.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
XORTX THERAPEUTICS INC. | Director/Miembro de la Junta | 16/06/2021 | 28/06/2023 |
Independent Dir/Board Member | 16/06/2021 | 28/06/2023 | |
Purdue Pharma (Canada)
Purdue Pharma (Canada) Pharmaceuticals: MajorHealth Technology Purdue Pharma (Canada) manufactures and markets pharmaceutical products. It products for the treatment of pain, respiratory disease, gastrointestinal disorders, and infection control. The firm include laxatives, bronchodilators, antiseptics, and analgesics. Purdue Pharma is headquartered in Pickering, Canada | Oficial de Cumplimiento | 01/01/2009 | 01/01/2018 |
Consejero General | 01/01/2009 | 01/01/2018 | |
Corporate Officer/Principal | 01/01/2019 | 01/12/2019 | |
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Oficial de Cumplimiento | 01/01/2009 | 01/01/2018 |
Consejero General | 01/01/2009 | 01/01/2018 | |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | Director/Miembro de la Junta | 01/01/2012 | 01/01/2012 |
PATHEON, INC. | Consejero General | 01/01/2008 | 01/01/2009 |
Secretario Corporativo | 01/01/2008 | 01/01/2009 | |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Consejero General | 01/07/2005 | 01/08/2007 |
Secretario Corporativo | 01/07/2005 | 01/08/2007 |
Formación de Jacqueline Le Saux.
University of Ottawa | Masters Business Admin |
University of Laurentian | Undergraduate Degree |
University of Toronto | Graduate Degree |
Estadísticas
Internacional
Canadá | 9 |
Estados Unidos | 2 |
Operativa
General Counsel | 4 |
Corporate Secretary | 2 |
Compliance Officer | 2 |
Sectorial
Health Technology | 7 |
Consumer Services | 4 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
XORTX THERAPEUTICS INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Patheon, Inc.
Patheon, Inc. Pharmaceuticals: MajorHealth Technology Patheon, Inc. provides drug development and manufacturing services to global pharmaceutical, biotechnology and specialty pharmaceutical companies. It operates through two segments: Commercial Manufacturing Outsourcing and Pharmaceutical Development Services. The Commercial Manufacturing Outsourcing segment manufactures prescription products in sterile dosage forms as well as solid and liquid conventional dosage forms. The Pharmaceutical Development Services segment provides a broad range of development services, including solid and sterile dosage forms. The company operates through four market segments: Biologics, Emerging Pharma, Generics and Large Pharma. Patheon was founded in 1974 and is headquartered in Mississauga, Canada. | Health Technology |
Purdue Pharma (Canada)
Purdue Pharma (Canada) Pharmaceuticals: MajorHealth Technology Purdue Pharma (Canada) manufactures and markets pharmaceutical products. It products for the treatment of pain, respiratory disease, gastrointestinal disorders, and infection control. The firm include laxatives, bronchodilators, antiseptics, and analgesics. Purdue Pharma is headquartered in Pickering, Canada | Health Technology |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | Health Technology |
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
- Bolsa de valores
- Insiders
- Jacqueline Le Saux
- Experiencia